Holen Sie sich die Stockscreener-App
58.00
4.17%
2.32
Handel nachbörslich:
58.55
0.55
+0.95%
Schlusskurs vom Vortag:
$55.68
Offen:
$55.5
24-Stunden-Volumen:
14,472
Relative Volume:
0.82
Marktkapitalisierung:
$161.58M
Einnahmen:
$23.93M
Nettoeinkommen (Verlust:
$-3.41M
KGV:
-50.88
EPS:
-1.14
Netto-Cashflow:
$-33.87M
1W Leistung:
+37.60%
1M Leistung:
+44.55%
6M Leistung:
+685.91%
1J Leistung:
+422.52%
1-Tages-Spanne:
$53.71
$59.00
1-Wochen-Bereich:
$43.00
$59.00
52-Wochen-Spanne:
$4.018
$59.00
Sol Gel Technologies Ltd Stock (SLGL) Company Profile
Firmenname
Sol Gel Technologies Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie SLGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLGL
Sol Gel Technologies Ltd
|
58.00 | 155.11M | 23.93M | -3.41M | -33.87M | -1.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sol Gel Technologies Ltd Stock (SLGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-19 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2019-12-31 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-31 | Bestätigt | JMP Securities | Mkt Outperform |
Sol Gel Technologies Ltd Aktie (SLGL) Neueste Nachrichten
Support Test: How Sol Gel Technologies Ltd. stock reacts to bond yieldsJuly 2025 WrapUp & Expert-Curated Trade Recommendations - ulpravda.ru
Can Sol Gel Technologies Ltd. stock hit record highs againJuly 2025 Reactions & Precise Buy Zone Tips - ulpravda.ru
Is Sol Gel Technologies Ltd. stock supported by strong cash flowsJuly 2025 Chart Watch & Consistent Return Investment Signals - ulpravda.ru
How Sol Gel Technologies Ltd. stock reacts to bond yieldsJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - ulpravda.ru
Does Sol Gel Technologies Ltd. stock trade at a discount to peersTrade Signal Summary & Short-Term High Return Ideas - ulpravda.ru
Opaleye Management Inc. Increases Stake in Sol-Gel Technologies Ltd - GuruFocus
Rosacea Market Research and Forecast Report 2025-2035: Galderma, AbbVie, Bausch Health, Journey Medical, and Sol-Gel Drive Innovation Through Expanded R&D and Clinical TrialsResearchAndMarkets.com - The AI Journal
Opaleye Management Inc. Buys 22,497 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock - Defense World
Opaleye Management Inc. Acquires 35,169 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock - Defense World
Market Moves: Why Sol Gel Technologies Ltd stock could see breakout soonAnalyst Upgrade & Weekly Top Stock Performers List - moha.gov.vn
Weekly Analysts’ Ratings Changes for Sol-Gel Technologies (SLGL) - Defense World
Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases $361,500.30 in Stock - MarketBeat
Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Purchases 35,169 Shares of Stock - MarketBeat
Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases $10,831.60 in Stock - MarketBeat
Insider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Buys 1,019 Shares of Stock - MarketBeat
Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases $67,771.68 in Stock - MarketBeat
We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Easily Afford To Drive Business Growth - Yahoo Finance
Sol-Gel Technologies (SLGL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
What is HC Wainwright's Estimate for SLGL FY2025 Earnings? - MarketBeat
What analysts say about Sol Gel Technologies Ltd stockAI-Driven Market Analysis & Small Investment Capital Gains - earlytimes.in
Sol-Gel Technologies’ (SLGL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Sol-Gel Technologies (NASDAQ:SLGL) Receives "Buy" Rating from HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates Sol-Gel Technologies (SLGL) Buy Recommendation - Nasdaq
SLGL: HC Wainwright & Co. Reiterates Buy Rating with $50 Price T - GuruFocus
What dividend safety score for Sol Gel Technologies Ltd. stockWeekly Market Summary & Free Community Supported Trade Ideas - Улправда
Will Sol Gel Technologies Ltd. stock gain from lower inflationJuly 2025 WrapUp & Community Shared Stock Ideas - Улправда
How rising interest rates impact Sol Gel Technologies Ltd. stock2025 Support & Resistance & Weekly Top Stock Performers List - Улправда
Insider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires 2,735 Shares of Stock - MarketBeat
Owner Opaleye Management Inc Buys 2,735 ($110.4K) Of Sol-Gel Technologies Ltd [SLGL] - TradingView — Track All Markets
How analysts rate Sol Gel Technologies Ltd. stock todayJuly 2025 Chart Watch & Fast Entry High Yield Tips - bolumsonucanavari.com
Is Sol Gel Technologies Ltd. stock a buy before product launchesQuarterly Profit Report & Daily Technical Forecast Reports - DonanımHaber
Why Sol Gel Technologies Ltd. stock could see breakout soonMarket Trend Review & Consistent Profit Alerts - DonanımHaber
Will Sol Gel Technologies Ltd. stock benefit from upcoming earnings reports2025 Valuation Update & Safe Capital Growth Plans - Улправда
Sol-Gel Technologies (SLGL) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Sol-Gel to End SGT-210 Trial in Darier Disease - marketscreener.com
Sol-Gel halts Darier disease treatment after failed clinical trial By Investing.com - Investing.com Nigeria
Why Is Small Cap Sol-Gel Tech Stock Falling Today? - Benzinga
Sol-Gel Technologies Updates Clinical Pipeline Following Phase 1b Results - TipRanks
Sol-Gel Technologies (SLGL) files update on SGT-210 Darier Phase 1b - Stock Titan
Sol-Gel halts studies for rare disease drug (SLGL:NASDAQ) - Seeking Alpha
Sol-Gel Technologies (SLGL) Discontinues SGT-210 Development for Darier Disease - GuruFocus
Sol-Gel halts Darier disease treatment after failed clinical trial - Investing.com
Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease - The Manila Times
Rare skin disease trial shows no clear gain, research focus shifts - Stock Titan
Owner Opaleye Management Inc Buys 87 ($3.5K) Of Sol-Gel Technologies Ltd [SLGL] - TradingView — Track All Markets
Sol-Gel Technologies (SLGL) insider files report on new share purchase - Stock Titan
Exit Recap: Will Sol Gel Technologies Ltd stock recover faster than peersQuarterly Market Review & Weekly Setup with ROI Potential - moha.gov.vn
Revenues Not Telling The Story For Sol-Gel Technologies Ltd. (NASDAQ:SLGL) After Shares Rise 30% - Sahm
Owner Opaleye Management Inc Buys 744 ($29.5K) Of Sol-Gel Technologies Ltd [SLGL] - TradingView — Track All Markets
What drives Sol Gel Technologies Ltd stock priceRisk Management Strategies & Big Profit Low Trading - earlytimes.in
What dividend safety score for Sol Gel Technologies Ltd stockShort Setup & Consistent Profit Trading Strategies - moha.gov.vn
Finanzdaten der Sol Gel Technologies Ltd-Aktie (SLGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sol Gel Technologies Ltd-Aktie (SLGL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Jan 05 '26 |
Buy |
42.98 |
198 |
8,510 |
447,331 |
| Opaleye Management Inc. | 10% Owner |
Dec 30 '25 |
Buy |
41.99 |
35,169 |
1,476,627 |
421,242 |
| Opaleye Management Inc. | 10% Owner |
Dec 31 '25 |
Buy |
41.99 |
22,497 |
944,744 |
443,739 |
| Opaleye Management Inc. | 10% Owner |
Dec 29 '25 |
Buy |
41.85 |
8,638 |
361,534 |
386,073 |
| Opaleye Management Inc. | 10% Owner |
Dec 26 '25 |
Buy |
41.68 |
1,626 |
67,765 |
377,435 |
| Opaleye Management Inc. | 10% Owner |
Dec 22 '25 |
Buy |
41.15 |
1,019 |
41,936 |
375,549 |
| Opaleye Management Inc. | 10% Owner |
Dec 23 '25 |
Buy |
41.66 |
260 |
10,832 |
375,809 |
| Opaleye Management Inc. | 10% Owner |
Dec 17 '25 |
Buy |
40.37 |
2,735 |
110,412 |
374,530 |
| Opaleye Management Inc. | 10% Owner |
Dec 12 '25 |
Buy |
40.00 |
87 |
3,480 |
371,795 |
| Opaleye Management Inc. | 10% Owner |
Dec 05 '25 |
Buy |
39.50 |
444 |
17,537 |
371,408 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):